New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...
Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with ...
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers Will Be Presented at the 2025 ASCO GU Symposium.
The new publication also builds on Veracyte’s extensive body of clinical evidence supporting its molecular tests in urology where its Decipher Prostate Genomic Classifier is the market leader in ...
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...
Genomic classifier tests, such as Decipher, Prolaris, and Oncotype DX Genomic Prostate Score, have been developed to improve the accuracy of risk classification and treatment decisions by ...
Tests like Decipher by Veracyte, Prolaris by Myriad Genetics, and Oncotype DX Genomic Prostate Score (GPS) by MDx offer a genetic snapshot of tumor aggressiveness, potentially catching things that ...
TAMPA, Fla. (Jan. 24, 2025) — A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris ...
and colleagues conducted a systematic review to summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician ...
Among 10 studies reporting risk reclassification after GC testing with one of three available tests -- Decipher, Prolaris, or the Oncotype DX Genomic Prostate Score (GPS), very low- or low-risk ...
Tests do not consistently influence ... conducted a systematic review to summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification ...